[go: up one dir, main page]

FI973089A7 - Human interleukin-1 receptor accessory protein - Google Patents

Human interleukin-1 receptor accessory protein Download PDF

Info

Publication number
FI973089A7
FI973089A7 FI973089A FI973089A FI973089A7 FI 973089 A7 FI973089 A7 FI 973089A7 FI 973089 A FI973089 A FI 973089A FI 973089 A FI973089 A FI 973089A FI 973089 A7 FI973089 A7 FI 973089A7
Authority
FI
Finland
Prior art keywords
human interleukin
accessory protein
receptor accessory
receptor
protein
Prior art date
Application number
FI973089A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI973089L (en
FI973089A0 (en
Inventor
Richard Anthony Chizzonite
Grace Wong Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI973089A7 publication Critical patent/FI973089A7/en
Publication of FI973089L publication Critical patent/FI973089L/en
Publication of FI973089A0 publication Critical patent/FI973089A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI973089A 1995-01-23 1996-01-17 Human interleukin-1 receptor helper protein FI973089A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23
PCT/EP1996/000181 WO1996023067A1 (en) 1995-01-23 1996-01-17 Human interleukin-1 receptor accessory protein

Publications (3)

Publication Number Publication Date
FI973089A7 true FI973089A7 (en) 1997-07-22
FI973089L FI973089L (en) 1997-07-22
FI973089A0 FI973089A0 (en) 1997-07-22

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973089A FI973089A0 (en) 1995-01-23 1996-01-17 Human interleukin-1 receptor helper protein

Country Status (19)

Country Link
EP (1) EP0808365A1 (en)
JP (1) JPH10512453A (en)
AR (1) AR003919A1 (en)
AU (1) AU4537096A (en)
BR (1) BR9606837A (en)
CA (1) CA2210724A1 (en)
CO (1) CO4480033A1 (en)
CZ (1) CZ208197A3 (en)
EA (1) EA199700265A1 (en)
FI (1) FI973089A0 (en)
HU (1) HUP9702458A2 (en)
IL (1) IL116796A0 (en)
MX (1) MX9705501A (en)
NO (1) NO973404L (en)
PE (1) PE64396A1 (en)
PL (1) PL321538A1 (en)
TR (1) TR199700652T1 (en)
WO (1) WO1996023067A1 (en)
ZA (1) ZA96333B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (en) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
IL136696A0 (en) 1997-12-23 2001-06-14 Immunex Corp Sigirr dna and polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002064630A2 (en) * 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
JP4212470B2 (en) 2001-06-26 2009-01-21 アムジェン フレモント インク． Antibody to OPGL
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
CA2456762A1 (en) * 2001-08-07 2003-02-20 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
KR101317045B1 (en) 2002-09-06 2013-10-16 암젠 인코포레이티드 Therapeutic human anti-il-1r1 monoclonal antibody
RS57852B1 (en) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Methods of reducing aggregation of il-1ra
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
ES2395087T3 (en) * 2004-05-05 2013-02-08 Valorisation-Recherche, Société en Commandite Interleukin-1 receptor antagonists, compositions and treatment methods
JP2008542685A (en) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット Cytokine receptor modifier and use thereof
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
US8709715B2 (en) 2008-03-26 2014-04-29 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
CA2824719C (en) * 2011-01-19 2020-06-02 Cantargia Ab Anti-il1rap antibodies and their use for treating solid tumours
CA2824387C (en) 2011-02-09 2019-09-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
MX2013013627A (en) * 2011-06-21 2014-04-25 Oncofactor Corp COMPOSITIONS AND METHODS FOR CANCER THERAPY AND DIAGNOSIS.
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201403875D0 (en) † 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP4428863A3 (en) 2015-05-11 2024-12-11 Natera, Inc. Methods and compositions for determining ploidy
JP7114460B2 (en) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー Monoclonal anti-IL-1RAcP antibody
RU2760913C2 (en) 2016-04-15 2021-12-01 Натера, Инк. Methods for identifying lung cancer
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CA3067637A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3781714B1 (en) 2018-04-14 2026-01-07 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
US20240224961A1 (en) * 2021-05-28 2024-07-11 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric il1rap
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use

Also Published As

Publication number Publication date
PL321538A1 (en) 1997-12-08
FI973089L (en) 1997-07-22
EP0808365A1 (en) 1997-11-26
BR9606837A (en) 1998-05-26
MX9705501A (en) 1997-10-31
NO973404D0 (en) 1997-07-23
WO1996023067A1 (en) 1996-08-01
PE64396A1 (en) 1997-01-28
CZ208197A3 (en) 1997-11-12
JPH10512453A (en) 1998-12-02
HUP9702458A2 (en) 1998-04-28
TR199700652T1 (en) 1998-02-21
FI973089A0 (en) 1997-07-22
CA2210724A1 (en) 1996-08-01
NO973404L (en) 1997-07-23
ZA96333B (en) 1996-07-23
AU4537096A (en) 1996-08-14
EA199700265A1 (en) 1998-04-30
AR003919A1 (en) 1998-09-30
CO4480033A1 (en) 1997-07-09
IL116796A0 (en) 1996-05-14

Similar Documents

Publication Publication Date Title
NO973404D0 (en) Human interleukin-1 receptor accessory protein
DE69634703D1 (en) Multiple adjustable seat unit
EP0957722A4 (en) ADJUSTABLE ARMREST ASSEMBLY
DE69612316D1 (en) Articulated armrest
DE69634739D1 (en) HEIGHT-ADJUSTABLE ARMRESTS
BR9704999A (en) Adjustable seat
DE69517674D1 (en) Adjustable seating arrangement
FI955400A0 (en) Chair
FI964322A7 (en) Adjustable armrest
DE69615850D1 (en) G PROTEIN COUPLED RECEPTOR HNFD578
KR970007965U (en) chair
KR970019006U (en) chair
HK1005249A (en) Human interleukin-1 receptor accessory protein
KR970007961U (en) Chair
KR960030269U (en) Chair
KR970031811U (en) Adjustable headrest
FI951187L (en) Seat
SE9503962D0 (en) Adjustable backrest
BR7502674U (en) Relax chair
KR960036852U (en) Removable armrest
KR970031423U (en) Relax seat
IT240237Y1 (en) REMOVABLE CHAIR
IT238069Y1 (en) ADJUSTABLE SEAT
KR960026466U (en) Fishing backrest
KR970031490U (en) Recliner device